TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30178187

Group type: EXPERIMENTAL
Intervention: Small tidal volume (STV) ventilation (3-5 mL/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Large tidal volume (LTV) ventilation (6-8 mL/kg)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Positive end-expiratory pressure (PEEP) of 5 cm H2O
Number of subjects: 58

Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP) of 0 cm H2O
Number of subjects: 58
Study: 27789115

Group type: EXPERIMENTAL
Intervention: Diazepam 5 mg orally
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Meclizine 25 mg orally
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study: 25393080

Group type: EXPERIMENTAL
Intervention: Melatonin/hypothermia group (N=15; received hypothermia and five daily enteral doses of melatonin 10 mg kg(‐1))
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Melatonin/hypothermia group
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hypothermia group (N=15; received 72‐h whole‐body cooling)
Number of subjects: 45
Study: 24412265

Group type: EXPERIMENTAL
Intervention: Foot-drop stimulator (FDS; Bioness L300) used for ambulation over 42 weeks after 8 physical therapy sessions
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Foot-drop stimulator (FDS; Bioness L300)
Number of subjects: 99

Group type: COMPARATOR
Intervention: No FDS used
Number of subjects: 99
Study: 22456475

Group type: EXPERIMENTAL
Intervention: Modified Blalock‐Taussig shunt
Number of subjects: 373

Group type: COMPARATOR
Intervention: Right‐ventricle‐to‐pulmonary‐artery shunt
Number of subjects: 373
Study: 19447844

Group type: EXPERIMENTAL
Intervention: Balance training
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 29
Study: 17270006

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (single dose)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg and esomeprazole 40 mg (single doses)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg (5 days' dosing)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg vs. rabeprazole 10 mg (5 days' dosing)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Esomeprazole (general)
Number of subjects: 80
Study: 15650984

Group type: EXPERIMENTAL
Intervention: diclofenac/paracetamol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: diclofenac
Number of subjects: 60

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 60
Study: 11786584

Group type: EXPERIMENTAL
Intervention: Isotretinoin added to hormonal therapy (arm 1)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Hormonal therapy alone (arm 2)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Isotretinoin-related toxicity
Number of subjects: 37
Study: 9538979

Group type: EXPERIMENTAL
Intervention: lisinopril
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: nifedipine
Number of subjects: 92

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 92
Study: 8011354

Group type: EXPERIMENTAL
Intervention: Fat stitch during wound closure
Number of subjects: 300

Group type: COMPARATOR
Intervention: No fat stitch during wound closure
Number of subjects: 300
Study: 2595326

Group type: EXPERIMENTAL
Intervention: EMLA cream 5%
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 1099047

Group type: EXPERIMENTAL
Intervention: Contingent administration of naloxone (N-allylnoroxymorphone) 500-2000 mg daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31828863

Group type: EXPERIMENTAL
Intervention: Wheat germ (WG) supplementation, 20g daily for 12 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 31191789

Group type: EXPERIMENTAL
Intervention: HIPER‐500® (deep heating device)
Number of subjects: 38

Group type: COMPARATOR
Intervention: SonoStim® (ultrasound)
Number of subjects: 38
Study: 28549131

Group type: EXPERIMENTAL
Intervention: I-wave protocol (4.3 ms interstimulus interval)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control protocol (3.5 ms interstimulus interval)
Number of subjects: 32
Study: 25397691

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL) + Propranolol (PP)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 66
Study: 23239836

Group type: EXPERIMENTAL
Intervention: Tolvaptan therapy
Number of subjects: 3196

Group type: EXPERIMENTAL
Intervention: Baseline AVP levels
Number of subjects: 3196
Study: 21670711

Group type: EXPERIMENTAL
Intervention: HIKCUPS intervention (6-month obesity intervention)
Number of subjects: 160
Study: 19543080

Group type: EXPERIMENTAL
Intervention: Nifedipine (30 mg/day) at bedtime
Number of subjects: 238

Group type: COMPARATOR
Intervention: Nifedipine (30 mg/day) upon awakening
Number of subjects: 238
Study: 16314017

Group type: EXPERIMENTAL
Intervention: Patients with right cerebral damage
Number of subjects: 34

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 34
Study: 15286880

Group type: EXPERIMENTAL
Intervention: Gatifloxacin IV followed by oral administration
Number of subjects: 56

Group type: COMPARATOR
Intervention: Ceftriaxone IV alone or in combination with erythromycin IV, followed by clarithromycin PO
Number of subjects: 56
Study: 11269535

Group type: EXPERIMENTAL
Intervention: Alendronate + Calcium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Only Calcium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Alendronate + Calcium (Control Group)
Number of subjects: 50
Study: 9437184

Group type: EXPERIMENTAL
Intervention: 80 mg daily soy isoflavones (45 mg genistein)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 7506165

Group type: EXPERIMENTAL
Intervention: Nimesulide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Naproxen
Number of subjects: 0
Study: 2825745

Group type: EXPERIMENTAL
Intervention: Dipyridamole 150/200 mg single doses
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dipyridamole 150/200 mg multiple doses (twice daily for 11 days)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dipyridamole (various doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dipyridamole (150/200 mg)
Number of subjects: 18
Study: 29250152

Group type: EXPERIMENTAL
Intervention: Percutaneous endoscopic lumbar discectomy
Number of subjects: 110

Group type: COMPARATOR
Intervention: Traditional open discectomy
Number of subjects: 110
Study: 28516835

Group type: EXPERIMENTAL
Intervention: CATS intervention (Cooperative Cross-Age Teaching)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CATS intervention (6 hr)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: CATS intervention
Number of subjects: 41
Study: 25711321

Group type: EXPERIMENTAL
Intervention: Immediate initiation of ART
Number of subjects: 4685

Group type: COMPARATOR
Intervention: Deferred initiation of ART
Number of subjects: 4685
Study: 23865122

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 80

Group type: COMPARATOR
Intervention: Gabapentin
Number of subjects: 80
Study: 20947492

Group type: EXPERIMENTAL
Intervention: Bilateral arm training with rhythmic auditory cueing (BATRAC)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Dose-matched therapeutic exercise (DMTE)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: CST atrophy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: VLSM
Number of subjects: 42
Study: 18318731

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL) with compression handpiece
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 10
Study: 17174807

Group type: COMPARATOR
Intervention: Intermediate-risk group (n = 139)
Number of subjects: 289

Group type: COMPARATOR
Intervention: First quartile of CHD risk
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: CFR
Number of subjects: 289

Group type: EXPERIMENTAL
Intervention: CVR
Number of subjects: 289
Study: 12713612

Group type: EXPERIMENTAL
Intervention: Cost-minimization analysis (CMA)
Number of subjects: 0
Study: 10945091

Group type: EXPERIMENTAL
Intervention: Reduction in systolic blood pressure among hypertensives
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Moderate alcohol intake
Number of subjects: 387
Study: 9198262

Group type: EXPERIMENTAL
Intervention: 5-month dynamic peripheral training programme
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study: 1347857

Group type: EXPERIMENTAL
Intervention: CGRP infusion at 0.6 micrograms/min for 4 hours, then up to a maximum of 10 days
Number of subjects: 117

Group type: COMPARATOR
Intervention: Standard best management (control)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: CGRP infusion
Number of subjects: 117
Study: 2988107

Group type: EXPERIMENTAL
Intervention: 30 g coarse wheat bran
Number of subjects: 20

Group type: COMPARATOR
Intervention: 30 g placebo bran
Number of subjects: 20
Study: 31257439

Group type: EXPERIMENTAL
Intervention: DNA methylation changes associated with prenatal smoking
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Independent samples from different stages across the life course
Number of subjects: 412
Study: 30353049

Group type: EXPERIMENTAL
Intervention: Complete Decongestive Therapy including manual lymphatic drainage (T+MLD)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Complete Decongestive Therapy without manual lymphatic drainage (T-MLD)
Number of subjects: 77
Study: 26739979

Group type: EXPERIMENTAL
Intervention: Overdentures with cusped teeth
Number of subjects: 20

Group type: COMPARATOR
Intervention: Overdentures with cuspless teeth
Number of subjects: 20
Study: 24154667

Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (LRZ; 0.01 mg/kg)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 27
Study: 22198049

Group type: EXPERIMENTAL
Intervention: Megestrol acetate (MA) plus l-carnitine, celecoxib, and antioxidants (arm 1)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Megestrol acetate (MA) alone (arm 2)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Both arms
Number of subjects: 104
Study: 20709257

Group type: EXPERIMENTAL
Intervention: Group A1 (15-minute smoking-cessation and 3-minute NRT adherence counseling at baseline, 1 week, and 4 weeks with free NRT for 2 weeks)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Group A2 (same as A1 but without adherence counseling)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Group B (10 minutes of quitting advice)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Group A1 and A2 (combined intervention groups)
Number of subjects: 719

Group type: COMPARATOR
Intervention: Group B (control group)
Number of subjects: 719

Group type: EXPERIMENTAL
Intervention: Self-reported quitting at 6 months
Number of subjects: 719
Study: 17385970

Group type: EXPERIMENTAL
Intervention: Psychological preparation for surgery
Number of subjects: 80

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 80
Study: 15749505

Group type: EXPERIMENTAL
Intervention: Bipolar radio frequency ablation
Number of subjects: 126

Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 126
Study: 17984132

Group type: EXPERIMENTAL
Intervention: Low dose (1 x 10(6) cells/0.1 mL, n = 9)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High dose (2 x 10(6) cells/0.1 mL, n = 10)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control (0.1 mL autologous plasma/injection, n = 9)
Number of subjects: 28
Study: 11070964

Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.125% bupivacaine
Number of subjects: 60
Study: 8853730

Group type: EXPERIMENTAL
Intervention: Zidovudine (ZDV) plus Lamivudine (3TC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Zidovudine (ZDV)
Number of subjects: 0
Study: 1518699

Group type: EXPERIMENTAL
Intervention: Brush-culture method
Number of subjects: 70
Study: 6438683

Group type: EXPERIMENTAL
Intervention: Sulpiride (800 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Chlorpromazine (CPZ) (400 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low concentrations of sulpiride or CPZ
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: High concentrations of sulpiride or CPZ
Number of subjects: 50
Study: 31256717

Group type: EXPERIMENTAL
Intervention: Intensive SBP goal (below 120 mm Hg)
Number of subjects: 9358

Group type: COMPARATOR
Intervention: Standard SBP goal (below 140 mm Hg)
Number of subjects: 9358

Group type: EXPERIMENTAL
Intervention: High medication burden
Number of subjects: 9358

Group type: COMPARATOR
Intervention: Intensive vs Standard treatment
Number of subjects: 9358

Group type: EXPERIMENTAL
Intervention: Medication burden
Number of subjects: 9358
Study: 29744647

Group type: EXPERIMENTAL
Intervention: Bone marrow grafting (percutaneous mesenchymal cell injection)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Core decompression (CD)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Bone marrow injection
Number of subjects: 125
Study: 27071759

Group type: COMPARATOR
Intervention: Duloxetine (55 mg/day, range 40-60 mg/day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Sertraline (146 mg/day, range 50-200 mg/day)
Number of subjects: 63
Study: 24696860

Group type: EXPERIMENTAL
Intervention: 3 LPM oxygen via a nasal cannula
Number of subjects: 340

Group type: COMPARATOR
Intervention: Room air only
Number of subjects: 340
Study: 22459699

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical nerve stimulation (TENS)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Interferential currents (IFCs)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Shortwave diathermy (SWD)
Number of subjects: 203

Group type: COMPARATOR
Intervention: Sham interventions (TENS sham, IFCs sham, SWD sham)
Number of subjects: 203
Study: 20202239

Group type: EXPERIMENTAL
Intervention: Topical treatment with 0.2% betamethasone-hyaluronidase cream twice a day for 8 weeks
Number of subjects: 59

Group type: COMPARATOR
Intervention: Circumcision
Number of subjects: 59
Study: 17907109

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 0.5 mg
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Tesaglitazar 1 mg
Number of subjects: 568

Group type: EXPERIMENTAL
Intervention: Tesaglitazar
Number of subjects: 568
Study: 16150142

Group type: EXPERIMENTAL
Intervention: Repeated measures ANOVA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multi-level analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cross-sectional analysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Complete case analysis
Number of subjects: 0
Study: 11821087

Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 172

Group type: COMPARATOR
Intervention: No Hormone Replacement Therapy
Number of subjects: 172
Study: 10721039

Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute phenylalanine/tyrosine depletion (APTD)
Number of subjects: 0
Study: 7726526

Group type: EXPERIMENTAL
Intervention: Cloxacillin 2 g every 4 hours and Gentamicin 1.5 mg/kg every 8 hours for 2 weeks (Group A)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Teicoplanin 10 mg/kg/12 hours on days 1-3, 6 mg/kg/12 hours on days 4-7, and 7 mg/kg/24 hours on day 8 (Group B)
Number of subjects: 7
Study: 30268346

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) promethazine
Number of subjects: 170

Group type: COMPARATOR
Intervention: Intravenous (IV) Ondansetron
Number of subjects: 170
Study: 28122337

Group type: EXPERIMENTAL
Intervention: tivantinib
Number of subjects: 98

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: NLR > 3
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: vascular invasion
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: NLR status
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: NLR
Number of subjects: 98
Study: 26458508

Group type: EXPERIMENTAL
Intervention: TAVIE en santé (n=375)
Number of subjects: 750

Group type: COMPARATOR
Intervention: Websites (n=375)
Number of subjects: 750
Study: 23819659

Group type: EXPERIMENTAL
Intervention: methylprednisolone 80 mg + 5 mL of levobupivacaine without epinephrine + 3 mL of 0.9% saline solution
Number of subjects: 60

Group type: COMPARATOR
Intervention: methylprednisolone 80 mg + 8 mL of 0.9% saline solution
Number of subjects: 60
Study: 21174634

Group type: EXPERIMENTAL
Intervention: Body weight support treadmill training (BWSTT) without additional therapist or self-support of the upper limbs
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Gait training conditions requiring self-support of the upper limbs
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Participants holding on to a stable handrail during gait training
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Stable upper-limb support during gait training
Number of subjects: 17
Study: 18378926

Group type: EXPERIMENTAL
Intervention: Arthroscopic simulator training on a bench-top knee simulator
Number of subjects: 20

Group type: COMPARATOR
Intervention: No additional training (Control)
Number of subjects: 20
Study: 16015691

Group type: EXPERIMENTAL
Intervention: Itopride 150 mg t.i.d.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Itopride 300 mg t.i.d.
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Itopride 100 mg t.i.d.
Number of subjects: 26
Study: 12858319

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine patch
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 48
Study: 10542821

Group type: EXPERIMENTAL
Intervention: Aerobic activity group
Number of subjects: 174

Group type: COMPARATOR
Intervention: Stretching and toning group
Number of subjects: 174
Study: 8897082

Group type: EXPERIMENTAL
Intervention: Salmeterol (50 micrograms b.i.d., at 10 and 22 hr)
Number of subjects: 0
Study: 1853170

Group type: EXPERIMENTAL
Intervention: Sulfamethizole for 3 days
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Sulfamethizole for 10 days
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Pivmecillinam for 3 days
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Sulfamethizole treated groups
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Pivmecillinam treated group
Number of subjects: 264
Study: 6401908

Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 80 mg 4 times a day)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Pindolol (5 to 10 mg 2 times a day)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Propranolol and Pindolol (both)
Number of subjects: 23
Study: 31500602

Group type: EXPERIMENTAL
Intervention: Tailored and therapeutically guided internet-based intervention (IMI) program consisting of six guided IMIs (6-8 modules, duration: 6-8 weeks) targeting different symptoms.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (TAU+)
Number of subjects: 360
Study: 29573460

Group type: EXPERIMENTAL
Intervention: Poor self-rated oral health in older age group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Poor self-rated oral health in Guarani peoples
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fewer functional teeth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2 or more untreated decayed teeth
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normative need for extraction
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Normative need for restoration of one or more surfaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Toothache
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Difficulty speaking due to dental problems
Number of subjects: 0
Study: 27114074

Group type: EXPERIMENTAL
Intervention: Lenalidomide/dexamethasone plus high-dose chemotherapy and autologous stem cell transplantation followed by lenalidomide maintenance
Number of subjects: 282

Group type: COMPARATOR
Intervention: Lenalidomide/dexamethasone
Number of subjects: 282
Study: 25323254

Group type: EXPERIMENTAL
Intervention: Mental stress tasks
Number of subjects: 310

Group type: COMPARATOR
Intervention: Platelet aggregation responses to serotonin and epinephrine at rest
Number of subjects: 310
Study: 22837319

Group type: EXPERIMENTAL
Intervention: MLVA typing
Number of subjects: 1682

Group type: COMPARATOR
Intervention: PCR ribotyping
Number of subjects: 1682
Study: 20658205

Group type: EXPERIMENTAL
Intervention: Emergency portacaval shunt
Number of subjects: 211

Group type: COMPARATOR
Intervention: Endoscopic sclerotherapy followed by rescue portacaval shunt
Number of subjects: 211
Study: 19124377

Group type: EXPERIMENTAL
Intervention: Erdosteine 300 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine 600 mg
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 15755632

Group type: EXPERIMENTAL
Intervention: OncoVAX therapy (active specific immunotherapy using autologous tumor cells with BCG vaccine)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No therapy (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OncoVAX therapy
Number of subjects: 0
Study: 12464756

Group type: EXPERIMENTAL
Intervention: Psychoeducational nursing intervention based on the Progressively Lowered Stress Threshold model
Number of subjects: 237

Group type: COMPARATOR
Intervention: Routine information and referrals for case management, community‐based services, and support groups
Number of subjects: 237
Study: 10921218

Group type: EXPERIMENTAL
Intervention: Enzyme and radiotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 50
Study: 8748726

Group type: EXPERIMENTAL
Intervention: Standardized immunotherapy (IT) (Alpare)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 1697057

Group type: EXPERIMENTAL
Intervention: 4 week multidisciplinary inpatient pain management programme
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 9 week multidisciplinary outpatient programme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 7318354

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal dilation (PTD) for FMD
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgery for FMD
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal dilation (PTD) for atherosclerosis
Number of subjects: 30

Group type: COMPARATOR
Intervention: Surgery for atherosclerosis
Number of subjects: 30